Dr. Reddy's Laboratories Ltd (DRL), the country's second largest drug maker, has tied up with Hetero Drugs to sell the generic Sofosbuvir tablets (400mg) in India. The drug will make a significant difference in the diagnosis and treatment of Hepatitis C.
"The launch of Resof is in line with Dr Reddy's philosophy of offering 'innovative medicine at an affordable price' and will provide significant relief to patients, resulting in potential cure and a high barrier to resistance at an affordable price for those living with Hepatitis C," said G.V. Prasad, Co-chairman, DRL.
New Drug, Sofosbuvir, Found Very Efficient in Treating Chronic Hepatitis C Virus Infection
A new drug, Sofosbuvir, has been found very efficient in treating different types of chronic Hepatitis C Virus infection; it is in the third phase of clinical trials.
Advertisement
The Drug Controller General of India approved the drug for manufacture and marketing. "Clinical studies have indicated that Sofosbuvir 400 mg, in combination with other agents, achieved very high cure rates, while shortening the duration of the treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype," said DRL.
DRL has a non-exclusive licence agreement with Gilead Sciences to manufacture and sell generic versions of its chronic Hepatitis C medicines in 91 developing countries.
Source: Medindia
Source: Medindia
Hepatitis C
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C virus.
Advertisement
 Neonatal HepatitisNeonatal hepatitis is an inflammation of the liver that usually occurs in early infancy and is typically transmitted to the baby by the infected mother. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.